The health industry’s more than $1 trillion in “firepower” should deliver another strong year for deals, a new report shows.
Big biotechnology firms and their medical technology brethren will be active dealmakers in 2020 as companies look to fuel needed growth, according to a report released Monday by professional services firm EY. Cell and gene therapy firms are expected to continue to dominate biotech deals. EY sees the potential for almost $300 billion in deals even without a repeat of 2019’s mega-mergers.
